Celularity Inc., a biotechnology company developing allogeneic cell therapies and biomaterial products, has entered a multi-year research collaboration services agreement with Regeneron to support the research of Regeneron’s allogeneic cell therapy candidates. The agreement’s initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. The research will t...